Examination of relationship between quality of life and adverse events in the first -line treatment including cetuximab for KRAS wild-type unresectable colorectal cancer

Not Applicable

• Conditions: unresectable colorectal cancer

• Registration Number: JPRN-UMIN000010985
• Lead Sponsor: Epidemiological and Clinical research Information Network (ECRIN)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-19
• Study Completion: 2016-04-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

Not provided

Exclusion Criteria

1.Serious bone marrow suppression 2.Serious sensory disturbance 3.History of mental disturbance of cerebrovascular attack 4.Irradiation for evaluable disease 5.Severe stenosis of primary site 6.Serious drug hypersensitivity or a history of allergic reaction from drugs 7.Uncontrolled hypertension, diabetes, or hypercalcemia 8.Liver cirrhosis, hepatic failure or renal failure 9.Interstitial lung disease, pulmonary fibrosis or pulmonary emphysema. 10.Active infection 11.Heart insufficiency or history of heart insufficiency 12.Brain metastases 13.Massive pleural effusion, ascites or pericardial effusion. 14.Watery diarrhea 15.Active concomitant malignancy 16.Pregnant woman, possibility pregnant woman, or nursing woman 17.Patients considered ineligible for the trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified